KR20220170775A - 세포내 면역 반응의 억제를 통한 목적 단백질의 발현 향상용 재조합 벡터 및 이의 응용 - Google Patents
세포내 면역 반응의 억제를 통한 목적 단백질의 발현 향상용 재조합 벡터 및 이의 응용 Download PDFInfo
- Publication number
- KR20220170775A KR20220170775A KR1020220076795A KR20220076795A KR20220170775A KR 20220170775 A KR20220170775 A KR 20220170775A KR 1020220076795 A KR1020220076795 A KR 1020220076795A KR 20220076795 A KR20220076795 A KR 20220076795A KR 20220170775 A KR20220170775 A KR 20220170775A
- Authority
- KR
- South Korea
- Prior art keywords
- expression
- cells
- target protein
- recombinant vector
- vector
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 146
- 239000013598 vector Substances 0.000 title claims abstract description 108
- 230000014509 gene expression Effects 0.000 title claims abstract description 79
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 76
- 230000028993 immune response Effects 0.000 title description 4
- 230000003834 intracellular effect Effects 0.000 title description 3
- 101000643024 Homo sapiens Stimulator of interferon genes protein Proteins 0.000 claims abstract description 80
- 102100035533 Stimulator of interferon genes protein Human genes 0.000 claims abstract description 80
- 230000037361 pathway Effects 0.000 claims abstract description 75
- 230000004913 activation Effects 0.000 claims abstract description 36
- 239000000126 substance Substances 0.000 claims abstract description 20
- 210000004027 cell Anatomy 0.000 claims description 161
- 101710072850 Poxin Proteins 0.000 claims description 53
- 238000000034 method Methods 0.000 claims description 28
- 238000002659 cell therapy Methods 0.000 claims description 26
- 210000002865 immune cell Anatomy 0.000 claims description 18
- 210000000822 natural killer cell Anatomy 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 238000010367 cloning Methods 0.000 claims description 15
- 230000002708 enhancing effect Effects 0.000 claims description 15
- 230000015788 innate immune response Effects 0.000 claims description 12
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 10
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 7
- 102000004127 Cytokines Human genes 0.000 claims description 7
- 108090000695 Cytokines Proteins 0.000 claims description 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 230000007440 host cell apoptosis Effects 0.000 claims description 4
- 210000004443 dendritic cell Anatomy 0.000 claims description 2
- 210000002540 macrophage Anatomy 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 238000011144 upstream manufacturing Methods 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 230000035899 viability Effects 0.000 abstract description 11
- 230000006907 apoptotic process Effects 0.000 description 30
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 230000001965 increasing effect Effects 0.000 description 19
- 230000003013 cytotoxicity Effects 0.000 description 16
- 231100000135 cytotoxicity Toxicity 0.000 description 16
- 230000004083 survival effect Effects 0.000 description 14
- 102100031256 Cyclic GMP-AMP synthase Human genes 0.000 description 13
- 108030002637 Cyclic GMP-AMP synthases Proteins 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 238000012790 confirmation Methods 0.000 description 11
- 230000005855 radiation Effects 0.000 description 11
- 229960004679 doxorubicin Drugs 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 9
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 9
- 239000002246 antineoplastic agent Substances 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 238000002512 chemotherapy Methods 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 108091008146 restriction endonucleases Proteins 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 6
- 238000001959 radiotherapy Methods 0.000 description 6
- RFCBNSCSPXMEBK-INFSMZHSSA-N c-GMP-AMP Chemical class C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 RFCBNSCSPXMEBK-INFSMZHSSA-N 0.000 description 5
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 229960002378 oftasceine Drugs 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- XRILCFTWUCUKJR-INFSMZHSSA-N 2'-3'-cGAMP Chemical compound C([C@H]([C@H]1O)O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H]2N1C=NC2=C1NC(N)=NC2=O XRILCFTWUCUKJR-INFSMZHSSA-N 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 101000798396 Bacillus licheniformis Phenylalanine racemase [ATP hydrolyzing] Proteins 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000005251 gamma ray Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 108091028075 Circular RNA Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000007500 overflow downdraw method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000003151 transfection method Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 101150056413 Pim1 gene Proteins 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229950006073 cotinine Drugs 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000006676 mitochondrial damage Effects 0.000 description 1
- 231100001143 noxa Toxicity 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4646—Small organic molecules e.g. cocaine or nicotine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20210081233 | 2021-06-23 | ||
| KR1020210081233 | 2021-06-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220170775A true KR20220170775A (ko) | 2022-12-30 |
Family
ID=84538641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020220076795A KR20220170775A (ko) | 2021-06-23 | 2022-06-23 | 세포내 면역 반응의 억제를 통한 목적 단백질의 발현 향상용 재조합 벡터 및 이의 응용 |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR20220170775A (fr) |
| WO (1) | WO2022270946A1 (fr) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100184090A1 (en) * | 2007-07-17 | 2010-07-22 | Merck Serono Sa | Method for Generating Stable Cell Lines Expressing High Levels of a Protein of Interest |
| KR101809594B1 (ko) * | 2015-11-06 | 2017-12-15 | 한국생명공학연구원 | 목적 단백질 생산을 위한 발현 벡터 및 이를 이용한 목적 단백질의 과발현 방법 |
| BR112019010933A2 (pt) * | 2016-11-28 | 2019-10-01 | Aratinga Bio Aio | construções de vetor viral para expressão de adjuvantes genéticos que ativam a via de sting |
| WO2019035901A1 (fr) * | 2017-08-15 | 2019-02-21 | University Of Miami | Compositions et méthodes pour la modulation de la protéine sting |
-
2022
- 2022-06-23 WO PCT/KR2022/008954 patent/WO2022270946A1/fr active Application Filing
- 2022-06-23 KR KR1020220076795A patent/KR20220170775A/ko not_active Application Discontinuation
Non-Patent Citations (4)
| Title |
|---|
| Bai et al., Diabetes, 68(6):1099-1108 (2019) |
| Eaglesham et al., Nature, 566(7743):259-263 (2019) |
| Ni et al., PLoS Pathog., 14(8):e1007148 (2018) |
| Xia et al., Immunity, 48(4): 688-701 (2018) |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022270946A1 (fr) | 2022-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11931380B2 (en) | Inhibition of diacylglycerol kinase to augment adoptive T cell transfer | |
| US20220168419A1 (en) | Compositions and methods for treating autoimmune diseases and cancers | |
| CN111989108B (zh) | 利用rna去稳定元件协调基因表达 | |
| ES2776029T3 (es) | Terapias basadas en el control de la estabilidad y función de las células T reguladoras por medio de un eje neuropilina-1:semaforina | |
| CN108174607A (zh) | 用于遗传工程改造的细胞中调节抑制性相互作用的组合物和方法 | |
| US11639496B2 (en) | Reducing fratricide of immune cells expressing NKG2D-based receptors | |
| KR20140126357A (ko) | C1orf32 항체 및 이의 암 치료를 위한 용도 | |
| EP2632489B1 (fr) | Compositions ciblant le domaine extracellulaire soluble de l'e-cadhérine et méthodes de thérapie anticancéreuse apparentées | |
| JP5410416B2 (ja) | 血管形成の阻害のためのｒｔｅｆ−１変異体およびその使用 | |
| JP7475088B2 (ja) | ヒトメソセリンを特異的に認識する細胞表面分子、ｉｌ－７、及びｃｃｌ１９を発現する免疫担当細胞 | |
| CN109153989A (zh) | 表达免疫功能调控因子的免疫活性细胞及表达载体 | |
| JP2023535264A (ja) | キメラ抗原受容体及びその用途 | |
| US20150010561A1 (en) | Semaphorin 3C (Sema3C) Inhibitor Therapeutics, Methods, and Uses | |
| EP3373941A1 (fr) | Cellules immunitaires modifiées et leurs utilisations | |
| Lee et al. | Interleukin-18-mediated interferon-gamma secretion is regulated by thymosin beta 4 in human NK cells | |
| KR20220170775A (ko) | 세포내 면역 반응의 억제를 통한 목적 단백질의 발현 향상용 재조합 벡터 및 이의 응용 | |
| US10557140B2 (en) | CTLA-4-targeting trans-splicing ribozyme for delivery of chimeric antigen receptor, and use thereof | |
| WO2020141106A1 (fr) | Système de régulation de la transcription artificielle à régulation externe modifié à base de nfat modifié | |
| US20200115712A1 (en) | Compositions and methods for cancer immunotherapy | |
| KR101513702B1 (ko) | Phc2 발현을 억제하는 유전자를 포함하는 NKT 세포 활성 억제용 조성물 및 이를 이용한 면역억제제 | |
| EP2940040B1 (fr) | Fragment de hspbp1 comme agent antitumoral et pour la sensibilisation de cellules tumorales à des agents chimiothérapeutiques | |
| Eaton | Engineering Macrophages to Control the Foreign Body Reaction | |
| TW202242109A (zh) | 醫藥組合物及其用途 | |
| KR20130091044A (ko) | ＪｕｎＢ의 발현 또는 활성 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal |